SCHEDULE 13G/A: BML Investment Partners Discloses Significant 13.3% Stake in Aclaris Therapeutics

BML Investment Partners, L.P. has reported a 13.3% beneficial ownership stake in Aclaris Therapeutics, Inc., holding 14.25 million shares as of December 31, 2024.

Summary

• BML Investment Partners, L.P. filed an Amendment No. 3 to Schedule 13G, disclosing its beneficial ownership in Aclaris Therapeutics, Inc.
• As of December 31, 2024, BML Investment Partners, L.P. beneficially owns an aggregate of 14,250,000 shares of Aclaris Therapeutics, Inc. Common Stock.
• This ownership represents 13.3% of the total outstanding shares of the class of securities.
• BML Investment Partners, L.P. holds shared voting power and shared dispositive power over all 14,250,000 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, except for activities solely in connection with a nomination under Rule 240.14a-11.
• BML Investment Partners, L.P. is a Delaware limited partnership, with BML Capital Management, LLC as its sole general partner, and Braden M. Leonard as the managing member of BML Capital Management, LLC.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's operational or financial performance.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially signal confidence or a basis for future shareholder engagement.

Key Dates

Keywords

Aclaris Therapeutics, BML Investment Partners, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, pharmaceutical, biotechnology